Kinetic response of wild and mutant core codon 70 strains of HCV genotype 1b to pegylated interferon-α and ribavirin therapy

被引:2
|
作者
Hu, Zhongjie [1 ]
Liu, Ying [2 ]
Qiu, Lixia [1 ]
Fan, Zuopeng [1 ]
Nie, Wei [1 ]
Liang, Shan [1 ]
Jin, Ronghua [3 ]
机构
[1] Capital Med Univ, Beijing Youan Hosp, Dept Hepatitis & Tox Liver Dis C, Beijing 100069, Peoples R China
[2] Capital Med Univ, Beijing Youan Hosp, Management Ctr Med Record, Beijing 100069, Peoples R China
[3] Capital Med Univ, Beijing Youan Hosp, Beijing 100069, Peoples R China
关键词
Hepatitis C virus; Genotype; 1b; Amino acid 70 substitution; Interferon; Viral kinetics; HEPATITIS-C VIRUS; AMINO-ACID SUBSTITUTIONS; VIROLOGICAL RESPONSE; JAPANESE PATIENTS; COMBINATION THERAPY; INHIBITS INTERFERON; PREDICTIVE FACTORS; GENETIC-VARIATION; NON-A; PROTEIN;
D O I
10.1186/s12985-015-0451-9
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Background: Amino acid (aa) 70 substitution (R70Q/H) in the core protein of hepatitis C virus (HCV) genotype 1b has been shown to be one of the key factors in determining resistance for pegylated interferon-alpha plus ribavirin combination therapy (PEG-IFN alpha/RBV). But the exact mechanisms remain unclear. The aim of this study was to investigate the dynamic response of wild and mutant core codon 70 strains to PEG-IFN alpha/RBV treatment. Methods: One hundred twelve Chinese patients with chronic HCV 1b infection were enrolled and received a standard protocol of 48 weeks of PEG-IFN alpha/RBV therapy and 24 consecutive weeks of follow-up. Serial blood samples were obtained at pretreatment baseline, and again at weeks 2, 4, 8, 12, and 24 during therapy for the quantification of 70R and 70Q/H strains. Dynamic characteristics and association with early virological response (EVR), sustained virological response (SVR) and IL28B genotypes were analyzed. Results: Of the 112 patients enrolled in this study, 93.8 % (105/112) were infected with mixture of 70R and 70Q/H strains before treatment. The 70Q/H strain was dominant in 20.5 % of patients. 42.9 % of patients with dominant 70Q/H exhibited EVR versus 88.6 % of patients with dominant 70R (P < 0.001). Furthermore, 35.0 % of patients with dominant 70Q/H exhibited SVR versus 77.4 % with dominant 70R (P < 0.001). However, regardless of the dominant strain, virological response types or the IL28B SNP genotypes, 70Q/H strains always exhibited the same response to treatment as the 70R strains and the percentage of HCV harboring the 70Q/H substitution did not change significantly during treatment. Conclusions: Although the ratio of 70Q/H to 70R is related to the virological response, 70Q/H strains always exhibited the same response as the 70R strains during PEG-IFN alpha/RBV treatment. Substitution of R70Q/H alone is not enough to lead to resistance to therapy. Positive selection for 70Q/H induced by IFN alpha was not observed.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] IL28B SNP rs8099917 Is Strongly Associated with Pegylated Interferon-α and Ribavirin Therapy Treatment Failure in HCV/HIV-1 Coinfected Patients
    Aparicio, Ester
    Parera, Mariona
    Franco, Sandra
    Perez-Alvarez, Nuria
    Tural, Cristina
    Clotet, Bonaventura
    Angel Martinez, Miguel
    PLOS ONE, 2010, 5 (10):
  • [42] Phase 1b Study of Pegylated Interferon Lambda 1 With or Without Ribavirin in Patients with Chronic Genotype 1 Hepatitis C Virus Infection
    Muir, Andrew J.
    Shiffinan, Mitchell L.
    Zaman, Atif
    Yoffe, Boris
    de la Torre, Andrew
    Flamm, Steven
    Gordon, Stuart C.
    Marotta, Paul
    Vierling, John M.
    Lopez-Talavera, Juan Carlos
    Byrnes-Blake, Kelly
    Fontana, David
    Freeman, Jeremy
    Gray, Todd
    Hausman, Diana
    Hunder, Naomi N.
    Lawitz, Eric
    HEPATOLOGY, 2010, 52 (03) : 822 - 832
  • [43] An Open Pilot Study Exploring the Efficacy of Fluvastatin, Pegylated Interferon and Ribavirin in Patients with Hepatitis C Virus Genotype 1b in High Viral Loads
    Sezaki, Hitomi
    Suzuki, Fumitaka
    Akuta, Norio
    Yatsuji, Hiromi
    Hosaka, Tetsuya
    Kobayashi, Masahiro
    Suzuki, Yoshiyuki
    Arase, Yasuji
    Ikeda, Kenji
    Miyakawa, Yuzo
    Kumada, Hiromitsu
    INTERVIROLOGY, 2009, 52 (01) : 43 - 48
  • [44] Poor Response to Pegylated Interferon and Ribavirin in Older Women Infected with Hepatitis C Virus of Genotype 1b in High Viral Loads
    Hitomi Sezaki
    Fumitaka Suzuki
    Yusuke Kawamura
    Hiromi Yatsuji
    Tetsuya Hosaka
    Norio Akuta
    Masahiro Kobayashi
    Yoshiyuki Suzuki
    Satoshi Saitoh
    Yasuji Arase
    Kenji Ikeda
    Yuzo Miyakawa
    Hiromitsu Kumada
    Digestive Diseases and Sciences, 2009, 54
  • [45] RASSF1A and p16 promoter methylation and treatment response in chronic hepatitis C genotype 1b patients treated with pegylated interferon/ribavirin
    Kokanov, Nikola
    Krajnovic, Milena
    Cupic-Jovanovic, Snezana
    Kozik, Bojana
    Petrovic, Nina
    Bozovic, Ana
    Mandusic, Vesna
    ARCHIVES OF BIOLOGICAL SCIENCES, 2022, 74 (01) : 57 - 66
  • [46] The influence of host factors and sequence variability of the p7 region on the response to pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b in patients from Serbia
    Jovanovic-Cupic, Snezana
    Glisic, Sanja
    Stanojevic, Maja
    Nozic, Darko
    Petrovic, Nina
    Mandusic, Vesna
    Krajnovic, Milena
    ARCHIVES OF VIROLOGY, 2016, 161 (05) : 1189 - 1198
  • [47] HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b
    Pellicelli, Adriano M.
    Romano, Mario
    Stroffolini, Tommaso
    Mazzoni, Ettore
    Mecenate, Fabrizio
    Monarca, Roberto
    Picardi, Antonio
    Bonaventura, Maria Elena
    Mastropietro, Cristina
    Vignally, Pascal
    Andreoli, Arnaldo
    Marignani, Massimo
    D'Ambrosio, Cecilia
    Miglioresi, Lucia
    Nosotti, Lorenzo
    Mitidieri, Olga
    Gentilucci, Umberto Vespasiani
    Puoti, Claudio
    Barbaro, Giuseppe
    Barlattani, Angelo
    Furlan, Caterina
    Barbarini, Giorgio
    BMC GASTROENTEROLOGY, 2012, 12
  • [48] Prediction of sustained response to low-dose pegylated interferon alpha-2b plus ribavirin in patients with genotype 1b and high hepatitis C virus level using viral reduction within 2 weeks after therapy initiation
    Tamai, Hideyuki
    Shingaki, Naoki
    Shiraki, Tatsuya
    Tukuda, Hiroshi
    Mori, Yoshiyuki
    Moribata, Kosaku
    Enomoto, Shotaro
    Deguchi, Hisanobu
    Ueda, Kazuki
    Inoue, Izumi
    Maekita, Takao
    Iguchi, Mikitaka
    Yanaoka, Kimihiko
    Oka, Masashi
    Ichinose, Masao
    HEPATOLOGY RESEARCH, 2011, 41 (12) : 1137 - 1144
  • [49] Mutations in non-structural 5A and rapid viral response to pegylated interferon-α-2b plus ribavirin therapy are associated with therapeutic efficacy in patients with genotype 1b chronic hepatitis C
    Yano, Yoshihiko
    Seo, Yasushi
    Miki, Akira
    Saito, Masaya
    Kato, Hirotaka
    Hamano, Ken-Ichi
    Oya, Manabu
    Ouchi, Sachiko
    Fujisawa, Takashi
    Yamada, Hajime
    Yamashita, Yukimasa
    Tani, Satoshi
    Hirohata, Shigeya
    Yoon, Seitetsu
    Kitajima, Naoto
    Kitagaki, Kazunari
    Kawara, Akira
    Nakashima, Takatoshi
    Yu, Hosai
    Maeda, Tetsuo
    Azuma, Takeshi
    El-Shamy, Ahmed
    Hotta, Hak
    Hayashi, Yoshitake
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2012, 30 (05) : 1048 - 1052
  • [50] The clinical significance of HCV core antigen detection during Telaprevir/Peg-Interferon/Ribavirin therapy in patients with HCV 1 genotype infection
    Garbuglia, Anna Rosa
    Lionetti, Raffaella
    Lapa, Daniele
    Taibi, Chiara
    Visco-Comandini, Ubaldo
    Montalbano, Marzia
    D'Offizi, Gianpiero
    Castiglione, Filippo
    Capobianchi, Maria Rosaria
    Paci, Paola
    JOURNAL OF CLINICAL VIROLOGY, 2015, 69 : 68 - 73